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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of diosmin, troxerutin and hesperidin and maintenance 
of normal venous-capillary permeability pursuant to Article 13(5) 
of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Omikron Italia S.r.l., submitted pursuant to Article 13.5 of Regulation (EC) 
No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to a combination 
of diosmin, troxerutin and hesperidin and maintenance of normal venous-capillary permeability. The food that is 
a subject of the health claim, a combination of diosmin, troxerutin and hesperidin, is sufficiently characterised. 
The claimed effect, maintenance of normal venous-capillary permeability, is a beneficial physiological effect. 
No human intervention studies from which conclusions could be drawn for the scientific substantiation of 
the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been 
established between the consumption of a combination of diosmin, troxerutin and hesperidin and 
the maintenance of normal venous-capillary permeability. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Omikron Italia S.r.l., submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of Italy, the Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to a combination of diosmin, troxerutin and hesperidin and maintenance of normal venous-
capillary permeability. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application includes a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of diosmin, troxerutin and hesperidin 
in the form of a tablet. 
The claimed effect proposed by the applicant is “maintenance of physiological venous-capillary 
permeability”. The target population proposed by the applicant is “subjects presenting fatigability and 
feeling heaviness in the lower limbs, predisposition to capillary fragility and to alteration of venous-
capillary homeostasis, due to environmental factors or wrong lifestyle as prolonged standing and 
excessive nearness to heat sources”. 
EFSA requested the applicant to identify the specific physiological function of the body that is the 
subject of the claim, together with the outcome measures that may be used for the scientific evaluation 
of that function. The applicant stated that “physiological capillary permeability ensures physiological 
venous-capillary resorption of interstitial fluids” and that the product “improved capillary permeability 
in in vitro study”, which “can be measured in humans as the reduction of the volume of foot, ankle and 
leg”. 
The Panel considers that measurement of the changes of the volume of foot, ankle and leg is not 
a direct measure of “venous-capillary permeability”. 
The Panel considers that the health claim refers to the maintenance of normal physiological venous-
capillary permeability in healthy adults without signs or symptoms of chronic venous insufficiency 
(CVI) and does not include the treatment of CVI. 
The Panel considers that the maintenance of normal venous-capillary permeability is a beneficial 
physiological effect. 
The applicant identified 10 human studies, six reviews, three animal studies and one in vitro study as 
pertinent to the health claim. Only the in vitro study was performed with the food (i.e. a combination 
of diosmin, troxerutin and hesperidin) which is the subject of the claim. 
No human intervention study was performed with the food that is the subject of the claim. 
The Panel considers that, in the absence of evidence of an effect of a combination of diosmin, 
troxerutin and hesperidin on maintenance of normal venous-capillary permeability in humans, 
the results of the in vitro study cannot be used as a source of data for the scientific substantiation of 
the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of a combination of diosmin, troxerutin and hesperidin and 
maintenance of normal venous-capillary permeability. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the Community 
list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 15/04/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 21/05/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 17/06/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 10/07/2013. 
 On 25/09/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 02/10/2013 and restarted on 16/10/2013, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 16/10/2013, EFSA received the requested information (which was made available to 
EFSA in electronic format on 15/10/2013). 
 During its meeting on 11/12/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of diosmin, troxerutin and hesperidin and maintenance of normal venous-capillary 
permeability. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion 
on the scientific substantiation of a health claim related to a combination of diosmin, troxerutin and 
hesperidin and maintenance of normal venous-capillary permeability. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of a combination of diosmin, troxerutin and hesperidin, a positive assessment of its safety or a decision 
on whether a combination of diosmin, troxerutin and hesperidin is, or is not, classified as a foodstuff. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 
1924/2006. 
It should also be highlighted that the scope and the proposed wording of the claim and the conditions 
of use as proposed by the applicant may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Omikron Italia S.r.l., Viale Bruno Buozzi, 5, 00197 Roma, Italy. 
The application includes a request for the protection of proprietary data in accordance with Article 21 
of Regulation (EC) No 1924/2006 (information on manufacturing process and Fortini et al. (2010) 
study). 
Food/constituent as stated by the applicant 
According to the applicant, the food for which this health claim is made is a combination of diosmin 
(300 mg), troxerutin (300 mg) and hesperidin (100 mg) in the form of a tablet. 
Health relationship as claimed by the applicant 
According to the applicant, the claimed effect is a physiological stabilizing action on the interstitial 
connective tissue of vessels and on the inflammatory process. Flavonoids have several effects on 
vessels and on inflammatory processes. In particular, troxerutin has proven to be the more effective 
molecule, among the flavonoids, in maintaining venous-capillary permeability. Diosmin and 
hesperidin seem to increase and to strengthen the action on venous tone of troxerutin. The effect in 
maintaining normal vascular permeability is exercised through inhibition of pro-inflammatory 
mechanisms, through the synergistic action of the three components optimized through this specific 
formulation. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “the flavonoid mixture 
containing 300 mg of diosmin, 300 mg of troxerutin and 100 mg of hesperidin is a useful co adjuvant 
in maintaining physiological venous-capillary permeability”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of one tablet per day of a combination of diosmin (300 mg), 
hesperidin (300 mg) and troxerutin (100 mg). The target population proposed is subjects presenting 
with fatigue and a feeling of heaviness in the lower limbs and a predisposition to capillary fragility and 
alteration in the venous-capillary homeostasis, as a result of environmental factors or an inappropriate 
lifestyle, such as prolonged standing and excessive nearness to sources of heat. In these subjects, 
the intake of diosmin, troxerutin and hesperidin helps to maintain the trophism of the venous-capillary 
circulation and to prevent vascular dysfunction. Children and pregnant and lactating women should 
avoid consumption of the food that is the subject of this health claim. 
ASSESSMENT 
1. Characterisation of the food 
The food that is the subject of the health claim is a combination of diosmin, troxerutin and hesperidin. 
Diosmin is a semi-synthetic substance (modified hesperidin) with the chemical name: 5-hydroxy-2-(3-
hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one, with chemical formula 
C28H32O15 and molecular mass 608. 
Troxerutin (chemical name: 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-4-
oxo-4H-chromen-3-yl-6-O-(6-deoxy-β-D-mannopyranosyl)-β-D-glucopyranoside) is a 
trihydroxyethylated derivative of the natural flavonoid rutin with chemical formula C33H42O19 and 
molecular mass 742. It is present in tea, coffee, cereal grains and a variety of fruits and vegetables. 
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Hesperidin (chemical name: (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-
chromen-7-yl-6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside), with chemical formula 
C28H34O15 and molecular mass 610, is a flavanone glycoside constituting the main flavonoid in citrus 
fruits. 
One tablet contains 300 mg diosmin, 300 mg troxerutin and 100 mg hesperidin. 
Information about the manufacturing process, control specifications, stability and batch-to-batch 
variability has been provided. 
The Panel considers that the food, a combination of diosmin, troxerutin and hesperidin, which is 
the subject of the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect on human health 
The claimed effect proposed by the applicant is “the maintenance of physiological venous-capillary 
permeability”. The target population proposed by the applicant is “subjects presenting fatigability 
and feeling heaviness in the lower limbs, predisposition to capillary fragility and to alteration 
of venous-capillary homeostasis, due to environmental factors or wrong lifestyle as prolonged standing 
and excessive nearness to heat sources”. 
EFSA requested that the applicant identify the specific physiological function of the body that is 
the subject of the claim, together with the outcome measures which may be used for the scientific 
evaluation of that function. The applicant stated that “physiological capillary permeability ensures 
physiological venous-capillary resorption of interstitial fluids” and that the product “improved 
capillary permeability in in vitro study” which “can be measured in humans as the reduction of 
the volume of foot, ankle and leg”. 
The Panel considers that measurement of the changes of the volume of foot, ankle and leg is not 
a direct measure of “venous-capillary permeability”. 
The Panel considers that the health claim refers to the maintenance of normal venous-capillary 
permeability in healthy adults without signs or symptoms of chronic venous insufficiency (CVI) 
and does not include the treatment of CVI. 
The Panel considers that the maintenance of normal venous-capillary permeability is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed looking for publications related to marketed 
flavonoid formulations containing at least one of the functional substances present in the combination 
of diosmin, troxerutin and hesperidin ,which is the subject of the claim. Then a manual selection of 
papers was performed taking into consideration “the content and statistical significance”. 
The inclusion and exclusion criteria and the time-frame were not presented. The Panel notes that 
the search strategy was inadequately described, despite a request by EFSA to provide more detailed 
information about the search strategy. 
The applicant identified 10 human studies, six reviews, three animal studies and one in vitro study as 
pertinent to the health claim. Only the in vitro study was performed with the combination of the food 
which is the subject of the claim. 
In seven human studies submitted, the effect of different flavonoids (diosmin and beta-hydroxyethyl-
rutosides, beta-hydroxyethyl-rutosides, diosmin and hesperidin, and micronised purified flavanoid 
fraction (MPFF) consisting of diosmin and hesperidin), on symptoms of chronic venous disease was 
evaluated (Jantet, 2000; Belcaro et al., 2002; Danielsson et al., 2002; Jantet et al., 2002; Cesarone et 
al., 2006; Belcaro et al., 2008; Stuard et al., 2008). Other studies were related to pharmacokinetic 
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aspects (Kienzler et al., 2002; Kanaze et al., 2007) and the methods of detection of flavonoids in 
the human body (Spanakis et al., 2008) and did not address the effects of the food which is the subject 
of the claim. 
No human intervention study was performed with the food that is the subject of the claim. 
The Panel considers that, in the absence of evidence of an effect of a combination of diosmin, 
troxerutin and hesperidin on maintenance of normal venous-capillary permeability in humans, 
the results of the in vitro study (Fortini et al., 2010) cannot be used as a source of data for the scientific 
substantiation of the claim. 
The Panel concludes that a cause and effect relationship has not been established between 
the consumption of a combination of diosmin, troxerutin and hesperidin and maintenance of normal 
venous-capillary permeability. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, a combination of diosmin, troxerutin and hesperidin, which is the subject of 
the health claim, is sufficiently characterised. 
 The claimed effect is “maintenance of normal venous-capillary permeability”. The proposed 
target population is “subjects presenting fatigability and feeling heaviness in the lower limbs, 
predisposition to capillary fragility and to alteration of venous-capillary homeostasis, due to 
environmental factors or wrong lifestyle as prolonged standing and excessive nearness to heat 
sources”. Maintenance of normal venous-capillary permeability is a beneficial physiological 
effect. 
 A cause and effect relationship has not been established between the consumption of a 
combination of diosmin, troxerutin and hesperidin and maintenance of normal venous-
capillary permeability. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of diosmin, troxerutin and hesperidin and maintenance of 
normal venous-capillary permeability pursuant to Article 13(5) of Regulation (EC) No 1924/2006 
(Claim serial No: 0380_IT). April 2013. Submitted by Omikron Italia S.r.l. 
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ABBREVIATIONS 
CVI  chronic venous insufficiency 
MPFF  micronised purified flavanoid fraction 
 
 
